Glass House Brands (GLAS) Cost of Revenue (2020 - 2026)
Glass House Brands' (GLAS) quarterly Cost of Revenue came in at $30.5 million in Q1 2026, up 18.91% on a QoQ basis from $25.6 million in Q4 2025.
Glass House Brands (GLAS) Cost of Revenue (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Cost of Revenue data on file, last reported at $30.5 million in Q1 2026.
- On a quarterly basis, Cost of Revenue changed N/A year-over-year to $30.5 million in Q1 2026; TTM through Mar 2026 was $110.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $105.0 million, up 1.47% from the prior year.
- Cost of Revenue for Q1 2026 stood at $30.5 million, up from $25.6 million in the prior quarter.
- Over the last five years, Cost of Revenue for GLAS reached as high as $30.5 million in Q1 2026 and fell as low as $11.6 million in Q1 2022.
- Historically, Cost of Revenue has averaged $22.4 million across 5 years, with a median of $23.0 million in 2022.
- Across the five-year window, Cost of Revenue jumped 60.9% in 2022 and increased 10.58% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $20.7 million in 2022, then fell by 2.0% to $20.3 million in 2023, then climbed by 24.5% to $25.3 million in 2024, then grew by 1.52% to $25.6 million in 2025, then advanced by 18.91% to $30.5 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $30.5 million in Q1 2026, $25.6 million in Q4 2025, and $26.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 30.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.50 Mn |
| Mar 31, 2026 | 30.50 Mn |
| Dec 31, 2025 | 25.65 Mn |
| Dec 31, 2025 | 25.65 Mn |
| Sep 30, 2025 | 26.69 Mn |
| Sep 30, 2025 | 26.69 Mn |
| Jun 30, 2025 | 27.94 Mn |
| Jun 30, 2025 | 27.94 Mn |
| Jun 30, 2024 | 25.26 Mn |
| Jun 30, 2024 | 25.26 Mn |
| Jun 30, 2023 | 20.29 Mn |
| Jun 30, 2023 | 20.29 Mn |
| Dec 31, 2022 | 20.71 Mn |
| Dec 31, 2022 | 20.71 Mn |
| Sep 30, 2022 | 19.53 Mn |
| Sep 30, 2022 | 19.53 Mn |
| Jun 30, 2022 | 16.22 Mn |
| Jun 30, 2022 | 16.22 Mn |
| Mar 31, 2022 | 11.63 Mn |
| Mar 31, 2022 | 11.63 Mn |